RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pharming Group Stock

Pharming Group P/E 2024

Pharming Group P/E

-78.25

Ticker

PHARM.AS

ISIN

NL0010391025

WKN

A1H65A

As of Dec 18, 2024, Pharming Group's P/E ratio was -78.25, a 8.77% change from the -71.94 P/E ratio recorded in the previous year.

The Pharming Group P/E history

Pharming Group Aktienanalyse

What does Pharming Group do?

Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Pharming Group's P/E Ratio

The Price to Earnings (P/E) Ratio of Pharming Group is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Pharming Group's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Pharming Group is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Pharming Group’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Pharming Group stock

What is the price-to-earnings ratio of Pharming Group?

The price-earnings ratio of Pharming Group is currently -78.25.

How has the price-earnings ratio of Pharming Group changed compared to last year?

The price-to-earnings ratio of Pharming Group has increased by 8.77% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Pharming Group high compared to other companies?

Yes, the price-to-earnings ratio of Pharming Group is high compared to other companies.

How does an increase in the price-earnings ratio of Pharming Group affect the company?

An increase in the price-earnings ratio of Pharming Group would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Pharming Group affect the company?

A decrease in the price-earnings ratio of Pharming Group would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Pharming Group?

Some factors that influence the price-earnings ratio of Pharming Group are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Pharming Group pay?

Over the past 12 months, Pharming Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharming Group is expected to pay a dividend of 0 USD.

What is the dividend yield of Pharming Group?

The current dividend yield of Pharming Group is .

When does Pharming Group pay dividends?

Pharming Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pharming Group?

Pharming Group paid dividends every year for the past 0 years.

What is the dividend of Pharming Group?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pharming Group located?

Pharming Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pharming Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pharming Group from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Pharming Group pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Pharming Group in the year 2023?

In the year 2023, Pharming Group distributed 0 USD as dividends.

In which currency does Pharming Group pay out the dividend?

The dividends of Pharming Group are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Pharming Group stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Pharming Group

Our stock analysis for Pharming Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharming Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.